Zhanxin Yin Selected Research

Transjugular Intrahepatic Portasystemic Shunt

5/2022	Restoration of the gut microbiota is associated with a decreased risk of hepatic encephalopathy after TIPS.
1/2022	Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial.
1/2022	Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial.
12/2021	Long-term survival prediction for transjugular intrahepatic portosystemic shunt in severe cirrhotic ascites: assessment of ten prognostic models.
1/2021	Risk Stratification Based on Chronic Liver Failure Consortium Acute Decompensation Score in Patients With Child-Pugh B Cirrhosis and Acute Variceal Bleeding.
1/2021	Spleen Stiffness Performance in the Noninvasive Assessment of Gastroesophageal Varices after Transjugular Intrahepatic Portosystemic Shunts.
1/2021	Anticoagulation and Transjugular Intrahepatic Portosystemic Shunt for the Management of Portal Vein Thrombosis in Cirrhosis: A Prospective Observational Study.
6/2020	Long-term results of variceal bleeding management in 302 patients with chronic extrahepatic portal vein obstruction.
1/2019	TIPSS for variceal bleeding in patients with idiopathic non-cirrhotic portal hypertension: comparison with patients who have cirrhosis.
1/2019	Motor Cortex Mapping in Patients With Hepatic Myelopathy After Transjugular Intrahepatic Portosystemic Shunt.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Zhanxin Yin Research Topics

Disease

18	Hemorrhage 01/2022 - 01/2011
16	Fibrosis (Cirrhosis) 05/2022 - 01/2011
14	Thrombosis (Thrombus) 01/2022 - 01/2011
13	Hepatic Encephalopathy 05/2022 - 06/2010
12	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 01/2014
9	Ascites 01/2022 - 01/2011
7	Portal Hypertension 01/2019 - 11/2010
6	Neoplasms (Cancer) 06/2020 - 02/2009
4	Budd-Chiari Syndrome (Budd Chiari Syndrome) 01/2019 - 09/2014
3	End Stage Liver Disease 05/2022 - 01/2021
3	Liver Cirrhosis (Hepatic Cirrhosis) 01/2016 - 01/2011
2	Varicose Veins (Varicose Vein) 01/2021 - 06/2020
2	Brain Diseases (Brain Disorder) 01/2017 - 11/2010
1	Dysbiosis 05/2022
1	Peptic Ulcer (Peptic Ulcers) 01/2022
1	Gastritis 01/2022
1	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 07/2020
1	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 07/2020
1	Hepatorenal Syndrome 01/2019
1	Idiopathic Noncirrhotic Portal Hypertension 01/2019
1	Hydrothorax 01/2019
1	Liver Diseases (Liver Disease) 01/2019
1	Movement Disorders (Movement Disorder) 01/2019
1	Muscle Spasticity (Spastic) 01/2019
1	Peritonitis 01/2019
1	Spinal Cord Diseases 01/2019
1	Hepatic Insufficiency 01/2019
1	Jaundice (Icterus) 07/2016
1	Obstructive Jaundice (Cholestatic Jaundice) 07/2016
1	Klatskin Tumor 07/2016
1	Lymphatic Metastasis 07/2016
1	Cholangitis 06/2015
1	Splenomegaly 06/2012
1	Hypersplenism (Anemia, Splenic) 06/2012
1	Liver Failure 04/2012
1	Infections 04/2012
1	Stomach Neoplasms (Stomach Cancer) 02/2009
1	Carcinoma (Carcinomatosis) 02/2009

Drug/Important Bio-Agent (IBA)

7	Sorafenib (BAY 43-9006)FDA Link 10/2020 - 03/2014
3	BilirubinIBA 05/2022 - 09/2014
2	Biological ProductsIBA 05/2022 - 01/2014
2	AlbuminsIBA 01/2021 - 06/2020
2	Propranolol (Inderal)FDA LinkGeneric 01/2019 - 12/2018
1	SodiumIBA 12/2021
1	Warfarin (Coumadin)FDA LinkGeneric 01/2021
1	RivaroxabanIBA 01/2021
1	Enoxaparin (Lovenox)FDA LinkGeneric 01/2021
1	Protein SIBA 07/2020
1	factor V LeidenIBA 07/2020
1	Prothrombin (Factor II)IBA 07/2020
1	AntithrombinsIBA 07/2020
1	Protein CIBA 07/2020
1	thiamine triphosphorate (TTP)IBA 06/2020
1	Adrenergic beta-Antagonists (beta-Adrenergic Blocking Agents)IBA 06/2020
1	Serum AlbuminIBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 01/2019
1	6-propylchromone-2-carboxylic acid (PCCA)IBA 07/2016
1	AntigensIBA 07/2016
1	alpha-Fetoproteins (alpha-Fetoprotein)IBA 02/2016
1	Blood Coagulation Factors (Coagulation Factor)IBA 01/2015
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2014
1	CoagulantsIBA 02/2013
1	NitrogenIBA 02/2013
1	Urea (Carbamide)FDA LinkGeneric 02/2013
1	Alkaline PhosphataseIBA 02/2013
1	AnticoagulantsIBA 08/2012
1	Polytetrafluoroethylene (Teflon)FDA Link 11/2010
1	Doxorubicin (Adriamycin)FDA LinkGeneric 02/2009
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 02/2009
1	Prion ProteinsIBA 02/2009
1	Small Interfering RNA (siRNA)IBA 02/2009
1	Glycosylphosphatidylinositols (Glycosyl-Phosphatidylinositol)IBA 02/2009
1	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 02/2009
1	Pharmaceutical PreparationsIBA 02/2009
1	Membrane Proteins (Integral Membrane Proteins)IBA 02/2009

Therapy/Procedure

28	Surgical Portasystemic Shunt (Portosystemic Shunt) 05/2022 - 06/2010
28	Transjugular Intrahepatic Portasystemic Shunt 05/2022 - 11/2010
11	Stents 01/2022 - 11/2010
8	Therapeutics 06/2020 - 01/2011
2	Ligation 01/2019 - 12/2018
2	Conservative Treatment 01/2014 - 08/2012
2	Splenectomy 06/2012 - 06/2012
1	Transplantation 01/2019
1	Thrombolytic Therapy 10/2016
1	Palliative Care (Palliative Therapy) 06/2014
1	Drug Therapy (Chemotherapy) 02/2009